Yogarabindranath Swarna Nantha PhD, Shalini Vijayasingham MRCP, Noor Lita Adam MMed, Paranthaman Vengadasalam MMed, Mastura Ismail MMed, Norsiah Ali MMed, Li Cheng Chang MMed, Lena Yeap Lay Ling MSc, Thiam-Tsui Tee PhD, Yew-Hoong Cheah PhD
{"title":"Labisia pumila标准提取物（SKF7®）可降低肥胖患者的腰围百分比和腰高比","authors":"Yogarabindranath Swarna Nantha PhD, Shalini Vijayasingham MRCP, Noor Lita Adam MMed, Paranthaman Vengadasalam MMed, Mastura Ismail MMed, Norsiah Ali MMed, Li Cheng Chang MMed, Lena Yeap Lay Ling MSc, Thiam-Tsui Tee PhD, Yew-Hoong Cheah PhD","doi":"10.1111/dom.15229","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>Evidence from the literature points towards a viable choice of utilizing <i>Labisia pumila</i> to improve the metabolic profile in animal studies. To that end, this prospective study was designed to assess the health impact of the consumption of <i>L. pumila</i> standardized extract (SKF7®) on key parameters of obesity in humans such as body weight (BW), body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WHtR).</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>A dose-ranging analysis using SKF7® was conducted through a randomized, double-blind, multicentre, placebo-controlled, phase 2 clinical trial involving individuals with obesity (N = 133) between January 2020 and April 2021. The potential percentage of change was assessed in relation to BW, BMI, WC and WHtR.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Average treatment effect estimates (treatment group vs. placebo) show a statistically significant reduction in the percentage of change for BW (mean = −2.915; CI: −4.546, −1.285), BMI (−2.921; CI: −4.551, −1.291), WC (mean = −2.187; CI: −3.784, −0.589) and WHtR (mean = −2.294, CI: −3.908, −0.681) in the group with a total of 750 mg of SKF7® (<i>p</i> < .01). An incremental reduction in WC and WHtR was consistent with the gradual increase in the total daily concentration of SKF7® from 375 to 750 mg. WC and WHtR had higher effect size (<i>f</i> <sup>2</sup> = 0.11 and <i>f</i> <sup>2</sup> = 0.13 respectively) in comparison with BW and BMI.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SKF7® is potentially a novel therapeutic treatment for obesity, reflected by reductions in BW, BMI, WC and WHtR. The use of SKF7® suggests a dose-dependent reduction in abdominal obesity, exemplified by a decline in WC and WHtR.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"25 11","pages":"3298-3306"},"PeriodicalIF":5.4000,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15229","citationCount":"0","resultStr":"{\"title\":\"Labisia pumila standardized extract (SKF7®) reduces percentage of waist circumference and waist-to-height ratio in individuals with obesity\",\"authors\":\"Yogarabindranath Swarna Nantha PhD, Shalini Vijayasingham MRCP, Noor Lita Adam MMed, Paranthaman Vengadasalam MMed, Mastura Ismail MMed, Norsiah Ali MMed, Li Cheng Chang MMed, Lena Yeap Lay Ling MSc, Thiam-Tsui Tee PhD, Yew-Hoong Cheah PhD\",\"doi\":\"10.1111/dom.15229\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>Evidence from the literature points towards a viable choice of utilizing <i>Labisia pumila</i> to improve the metabolic profile in animal studies. To that end, this prospective study was designed to assess the health impact of the consumption of <i>L. pumila</i> standardized extract (SKF7®) on key parameters of obesity in humans such as body weight (BW), body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WHtR).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>A dose-ranging analysis using SKF7® was conducted through a randomized, double-blind, multicentre, placebo-controlled, phase 2 clinical trial involving individuals with obesity (N = 133) between January 2020 and April 2021. The potential percentage of change was assessed in relation to BW, BMI, WC and WHtR.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Average treatment effect estimates (treatment group vs. placebo) show a statistically significant reduction in the percentage of change for BW (mean = −2.915; CI: −4.546, −1.285), BMI (−2.921; CI: −4.551, −1.291), WC (mean = −2.187; CI: −3.784, −0.589) and WHtR (mean = −2.294, CI: −3.908, −0.681) in the group with a total of 750 mg of SKF7® (<i>p</i> < .01). An incremental reduction in WC and WHtR was consistent with the gradual increase in the total daily concentration of SKF7® from 375 to 750 mg. WC and WHtR had higher effect size (<i>f</i> <sup>2</sup> = 0.11 and <i>f</i> <sup>2</sup> = 0.13 respectively) in comparison with BW and BMI.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>SKF7® is potentially a novel therapeutic treatment for obesity, reflected by reductions in BW, BMI, WC and WHtR. The use of SKF7® suggests a dose-dependent reduction in abdominal obesity, exemplified by a decline in WC and WHtR.</p>\\n </section>\\n </div>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\"25 11\",\"pages\":\"3298-3306\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2023-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15229\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/dom.15229\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.15229","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Labisia pumila standardized extract (SKF7®) reduces percentage of waist circumference and waist-to-height ratio in individuals with obesity
Aim
Evidence from the literature points towards a viable choice of utilizing Labisia pumila to improve the metabolic profile in animal studies. To that end, this prospective study was designed to assess the health impact of the consumption of L. pumila standardized extract (SKF7®) on key parameters of obesity in humans such as body weight (BW), body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WHtR).
Materials and Methods
A dose-ranging analysis using SKF7® was conducted through a randomized, double-blind, multicentre, placebo-controlled, phase 2 clinical trial involving individuals with obesity (N = 133) between January 2020 and April 2021. The potential percentage of change was assessed in relation to BW, BMI, WC and WHtR.
Results
Average treatment effect estimates (treatment group vs. placebo) show a statistically significant reduction in the percentage of change for BW (mean = −2.915; CI: −4.546, −1.285), BMI (−2.921; CI: −4.551, −1.291), WC (mean = −2.187; CI: −3.784, −0.589) and WHtR (mean = −2.294, CI: −3.908, −0.681) in the group with a total of 750 mg of SKF7® (p < .01). An incremental reduction in WC and WHtR was consistent with the gradual increase in the total daily concentration of SKF7® from 375 to 750 mg. WC and WHtR had higher effect size (f2 = 0.11 and f2 = 0.13 respectively) in comparison with BW and BMI.
Conclusions
SKF7® is potentially a novel therapeutic treatment for obesity, reflected by reductions in BW, BMI, WC and WHtR. The use of SKF7® suggests a dose-dependent reduction in abdominal obesity, exemplified by a decline in WC and WHtR.
期刊介绍：
Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
